Jeff Jones
Stock Analyst at Oppenheimer
(4.61)
# 883
Out of 4,455 analysts
274
Total ratings
42.4%
Success rate
18%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Reiterated: Buy | $55 | $26.40 | +108.33% | 13 | Jun 26, 2026 | |
| ODTX Odyssey Therapeutics | Reiterated: Buy | $40 | $18.13 | +120.63% | 2 | Jun 18, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | $54 → $52 | $8.74 | +494.97% | 23 | Jun 17, 2026 | |
| ACRV Acrivon Therapeutics | Initiated Coverage: Buy | $8 | $1.68 | +376.19% | 1 | Jun 15, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $45 | $16.72 | +169.14% | 1 | Jun 15, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Buy | $13 | $3.04 | +327.63% | 31 | Jun 1, 2026 | |
| AVBP ArriVent BioPharma | Reiterated: Buy | $50 | $34.00 | +47.06% | 8 | Jun 1, 2026 | |
| MDWD MediWound | Maintained: Buy | $34 → $32 | $15.24 | +109.97% | 5 | May 28, 2026 | |
| CRVS Corvus Pharmaceuticals | Reiterated: Buy | $33 | $13.49 | +144.63% | 17 | May 15, 2026 | |
| CMMB Chemomab Therapeutics | Maintained: Buy | $25 | $1.59 | +1,472.33% | 22 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 → $66 | $29.03 | +127.35% | 8 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $5 | $1.19 | +320.17% | 16 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $34.01 | +47.02% | 10 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $5.00 | +100.00% | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $7 | $4.16 | +68.27% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $41 → $40 | $13.34 | +199.85% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $86 | $30.88 | +178.50% | 7 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.52 | - | 20 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 | $108.12 | +10.99% | 12 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $16 | $5.35 | +199.07% | 4 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $20 | $5.61 | +256.51% | 2 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.14 | - | 22 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.06 | n/a | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $5.20 | n/a | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.27 | n/a | 5 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.93 | n/a | 4 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.601 | n/a | 4 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $3.09 | n/a | 3 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.000001 | n/a | 2 | Jul 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.0015 | n/a | 1 | Sep 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $49.10 | n/a | 1 | Jun 22, 2021 |
Alumis
Jun 26, 2026
Reiterated: Buy
Price Target: $55
Current: $26.40
Upside: +108.33%
Odyssey Therapeutics
Jun 18, 2026
Reiterated: Buy
Price Target: $40
Current: $18.13
Upside: +120.63%
Corbus Pharmaceuticals Holdings
Jun 17, 2026
Reiterated: Buy
Price Target: $54 → $52
Current: $8.74
Upside: +494.97%
Acrivon Therapeutics
Jun 15, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $1.68
Upside: +376.19%
Ascentage Pharma Group International
Jun 15, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $16.72
Upside: +169.14%
Perspective Therapeutics
Jun 1, 2026
Reiterated: Buy
Price Target: $13
Current: $3.04
Upside: +327.63%
ArriVent BioPharma
Jun 1, 2026
Reiterated: Buy
Price Target: $50
Current: $34.00
Upside: +47.06%
MediWound
May 28, 2026
Maintained: Buy
Price Target: $34 → $32
Current: $15.24
Upside: +109.97%
Corvus Pharmaceuticals
May 15, 2026
Reiterated: Buy
Price Target: $33
Current: $13.49
Upside: +144.63%
Chemomab Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $25
Current: $1.59
Upside: +1,472.33%
May 15, 2026
Reiterated: Buy
Price Target: $62 → $66
Current: $29.03
Upside: +127.35%
May 13, 2026
Maintained: Buy
Price Target: $6 → $5
Current: $1.19
Upside: +320.17%
May 13, 2026
Reiterated: Buy
Price Target: $50
Current: $34.01
Upside: +47.02%
May 8, 2026
Reiterated: Buy
Price Target: $10
Current: $5.00
Upside: +100.00%
May 8, 2026
Reiterated: Buy
Price Target: $6 → $7
Current: $4.16
Upside: +68.27%
May 8, 2026
Maintained: Buy
Price Target: $41 → $40
Current: $13.34
Upside: +199.85%
Apr 20, 2026
Maintained: Buy
Price Target: $86
Current: $30.88
Upside: +178.50%
Mar 2, 2026
Rated: Hold
Price Target: n/a
Current: $2.52
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $120
Current: $108.12
Upside: +10.99%
Aug 15, 2025
Maintained: Buy
Price Target: $17 → $16
Current: $5.35
Upside: +199.07%
Aug 14, 2025
Maintained: Buy
Price Target: $19 → $20
Current: $5.61
Upside: +256.51%
Aug 8, 2025
Maintained: Hold
Price Target: n/a
Current: $1.14
Upside: -
Oct 29, 2024
Rated: Hold
Price Target: n/a
Current: $7.06
Upside: n/a
Aug 14, 2024
Maintained: Hold
Price Target: n/a
Current: $5.20
Upside: n/a
Nov 30, 2023
Maintained: Buy
Price Target: n/a
Current: $3.27
Upside: n/a
Nov 10, 2023
Maintained: Hold
Price Target: n/a
Current: $1.93
Upside: n/a
Nov 7, 2023
Maintained: Buy
Price Target: n/a
Current: $0.601
Upside: n/a
Apr 28, 2023
Rated: Buy
Price Target: n/a
Current: $3.09
Upside: n/a
Jul 20, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Sep 30, 2021
Reiterated: Hold
Price Target: n/a
Current: $0.0015
Upside: n/a
Jun 22, 2021
Maintained: Buy
Price Target: $37
Current: $49.10
Upside: n/a